India's drug pricing regulator has demanded explanations from 65 domestic and global drugmakers for selling new forms of essential diabetes and antibiotic drugs without its approval. The move could bring penalties for the drugmakers, among them Abbott Laboratories, Sanofi, Novartis and Indian firms such as Sun Pharmaceutical Industries and Lupin, the National Pharmaceutical Pricing Authority (NPPA) said on its website. Wednesday's action is the pricing authority's latest move to tighten control of drug prices, piling pressure on drugmakers grappling with slowing ...
Drug pricing regulator clamps down on drug cocktails
Sun Pharma will check every product listed in regulator's notice to ascertain its status